8-K

                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15 (d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

         Date of Report (Date of earliest event reported): June 12, 2006
                            POINT THERAPEUTICS, INC.
               (Exact Name of Registrant as Specified in Charter)

                       DELAWARE                        0-19410
              (State or Other Jurisdiction    (Commission File Number)
                      of Incorporation)

                 155 FEDERAL STREET, BOSTON, MASSACHUSETTS 02110
                    (Address of Principal Executive Offices)

       Registrant's telephone number, including area code: (617) 933-2130

                                       N/A

          (Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-4(c))



Item 8.01    Other Events

             Point Therapeutics, Inc. ("Point") issued a press release on
             June 12, 2006 announcing that they presented a preclinical
             poster on Point's lead diabetes compound, PT-630, at the
             American Diabetes Association 66th Annual Scientific Sessions
             on Sunday, June 11, 2006.

             A copy of the press release dated June 12, 2006 is being filed
             as Exhibit 99.1 to this Current Report on Form 8-K.



Item 9.01    Financial Statements and Exhibits.

             (c) Exhibits.

             99.1 - Press release issued by Point dated June 12, 2006.



                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                   POINT THERAPEUTICS, INC.


June 13, 2006                         By:  /s/ Donald R. Kiepert, Jr.
                                           -------------------------
                                    Name:  Donald R. Kiepert, Jr.
                                   Title:  President, Chief Executive Officer




                                  EXHIBIT INDEX

The following exhibit is filed herewith:

Exhibit     Description
- -------     -----------
99.1        Point Therapeutics, Inc. ("Point") issued a press release on
            June 12, 2006 announcing that they presented a preclinical
            poster on Point's lead diabetes compound, PT-630, at the
            American Diabetes Association 66th Annual Scientific Sessions
            on Sunday, June 11, 2006.

EX-99.1

                                                                    Exhibit 99.1

 Point Therapeutics' Diabetes Program Presented at American Diabetes
             Association 66th Annual Scientific Sessions;
             Chronic Administration of PT-630 Results in
      Triglyceride Reduction and other Anti-Diabetes Activities

    BOSTON--(BUSINESS WIRE)--June 12, 2006--Point Therapeutics, Inc.
(NASDAQ: POTP) presented a preclinical poster on the Company's lead
diabetes compound, PT-630, at the American Diabetes Association 66th
Annual Scientific Sessions on Sunday, June 11, 2006. PT-630 is an
inhibitor of DPP-4, which is a widely recognized target for the
treatment of diabetes.
    During this presentation, the Company presented the structure of
PT-630 for the first time. In addition, the Company presented head to
head preclinical data that differentiated PT-630 from both a
cyanopyrrolidine (CP) DPP-4 inhibitor and from metformin in studies in
Zucker Diabetic Fatty (ZDF) rats.
    In single dose acute studies of PT-630 and the CP-inhibitor,
PT-630 increased insulin secretion, reduced glucose excursion and
increased GLP-1 levels at similar levels to the CP-inhibitor in
animals. However, even with a single dose administration, PT-630
demonstrated longer term benefits in both elevation of GLP-1 levels
{24 and 48 oral glucose tolerance test (OGTT)} and lowering of plasma
glucose (4 hours post OGTT) at later times than the CP-inhibitor.
    In a chronic dosing study of PT-630, the CP-inhibitor and
metformin, PT-630 is differentiated from both the CP-inhibitor and
metformin in animals. After 44 days of daily dosing, PT-630 was more
effective than the other two study compounds in improving parameters
associated with the progression of type 2 diabetes. Specifically,
there were improvements in whole body sensitivity to insulin, a 50%
reduction in fasting plasma triglycerides and glucose levels and a
1.7% reduction (a 26.4% reduction compared to the controlled treated
group) in HbA1c. There were no such reductions in triglycerides and
glucose levels with metformin and the CP-inhibitor, and HbA1c was only
reduced by 0.9% and 0.5%, respectively, with metformin and the
CP-inhibitor. All of the above suggests the ability of PT-630 to
achieve glucose control in type 2 diabetes over the long-term.
    "The fact that in preclinical studies, PT-630, even with a
single-dose administration, demonstrates longer term benefits in both
elevation of GLP-1 levels and lowering of plasma glucose at later
times than the CP-inhibitor suggest that PT-630 is a longer lasting
inhibitor of DPP-4 than the CP-inhibitor," said Nazneen Aziz, Vice
President of External Research at Point Therapeutics. "The cumulative
benefit of PT-630 in chronic dosing preclinical studies is also
promising because it suggests that PT-630 may have more comprehensive
anti-diabetes activity than both of the other compounds evaluated when
metabolic parameters associated with long-term progression of the
disease are measured."

    About PT-630:

    PT-630, Point Therapeutics' lead diabetes compound, is an
inhibitor of DPP-4, which is a widely recognized target in the
treatment of diabetes. DPP-4 degrades the active form of GLP-1, an
intestinal peptide hormone responsible for regulating blood glucose
levels. When DPP-4 is inhibited, it leads to an elevation in the
circulating pool of active GLP-1, thereby greatly improving the
control of blood glucose levels in type 2 diabetes. Active GLP-1 is
also thought to have beneficial effects on pancreatic beta cell mass.

    About Point Therapeutics, Inc.:

    Point is a Boston-based biopharmaceutical company developing a
portfolio of dipeptidyl peptidase (DPP) inhibitors for use in cancer,
type 2 diabetes and as vaccine adjuvants. Point is currently studying
its lead product candidate, talabostat, in two Phase 3 trials in
non-small cell lung cancer. Point is also studying talabostat in
several Phase 2 trials, including as a single-agent in metastatic
melanoma, in combination with cisplatin in metastatic melanoma, in
combination with rituximab in advanced chronic lymphocytic leukemia,
and in combination with gemcitabine in metastatic pancreatic cancer.
In addition, Point's portfolio includes two other DPP inhibitors in
preclinical development--PT-630 for type 2 diabetes and PT-510 as a
vaccine adjuvant.

    Certain statements contained herein are not strictly historical
and are "forward looking" statements as defined in the Private
Securities Litigation Reform Act of 1995. This information includes
statements with respect to the company's clinical development programs
and the timing of initiation and completion of its clinical trials.
Forward-looking statements are statements that are not historical
facts, and can be identified by, among other things, the use of
forward-looking language, such as "believes," "feels," "expects,"
"may," "will," "should," "seeks," "plans," "schedules to," "projects,"
"anticipates" or "intends" or the negative of those terms, or other
variations of those terms of comparable language, or by discussions of
strategy or intentions. A number of important factors could cause
actual results to differ materially from those projected or suggested
in the forward looking statement, including the risk factors described
in Point's quarterly report on Form 10-Q for the quarter ended March
31, 2006 and from time to time in Point's periodic and other reports
filed with the Securities and Exchange Commission.

    CONTACT: Point Therapeutics, Inc.
             Sarah Cavanaugh, 617-933-7508
             Director, Corporate Communications